Assessing the Economics of Dengue: Results from a Systematic Review of the Literature and Expert Survey

PharmacoEconomics

Volumn 33, Issue 11, 2015, Pages 1107-1135

  Constenla, Dagna ^a,b   Garcia, Cristina ^a   Lefcourt, Noah ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Dengue Vaccine Initiative (DVI)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE;

BIBLIOGRAPHIC DATABASE; CHECKLIST; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DATA COLLECTION METHOD; DENGUE; DISABILITY; DISEASE TRANSMISSION; ECONOMIC EVALUATION; EMBASE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH SURVEY; HOSPITAL CARE; HUMAN; MALAYSIA; MEDICAL EXPERT; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); NICARAGUA; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; VACCINATION; COST BENEFIT ANALYSIS; ECONOMICS; PUBLIC HEALTH; QUESTIONNAIRE;

CHECKLIST; COST-BENEFIT ANALYSIS; DENGUE; HUMANS; PUBLIC HEALTH; SURVEYS AND QUESTIONNAIRES;

EID: 84944513311     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-015-0294-7     Document Type: Review

References (48)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496:504–7. doi:10.1038/nature12060.
2. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012;6:e1760. doi:10.1371/journal.pntd.0001760.
3. Capeding MR, Tran NH, Hadinegaro SR et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomized, observer-masked, placebo-controlled trial. Lancet 2014;384(9951):1358–65. doi:10.1016/S0140-6736(14)61060-6.
4. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children and adolescents in aged 9 to 16 years in Latin America. N Engl J Med. 2014;. doi:10.1056/NEJMoa1411037.
5. Constenla D, Lefcourt N, Garcia C. Expert Panel on Developing Guidelines for the Estimation of Costs of Dengue in the Latin American and Caribbean Region. In: Proceedings of the workshop on developing regional guidelines of costs of dengue with a focus on the Latin America and Caribbean Region. Available from: http://www.denguevaccines.org/sites/default/files/Proceedings%20Guidelines%20Workshop.pdf. Accessed 11 Aug 2014.
6. Constenla D, Lefcourt N, Garcia C. Expert consensus-building for developing guidelines: lessons learned from a dengue economics workshop. Rev Panam Salud Publica. 2013;34(3):198–203.
7. Luz PM, Grinsztejn B, Galvani AP. Disability adjusted life years lost to dengue in Brazil. Trop Med Int Health. 2009;14(2):237–46.
8. Cho-Min N. Assessment of dengue hemorrhagic fever in Myanmar. Southeast Asian J Trop Med Public Health. 2000;31(4):636–41.
9. Meltzer MI, Rigau-Perez JG, Clark GG, Reiter P, Gubler DJ. Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984–1994. Am J Trop Med Hyg. 1998;59(2):265–71.
10. Ditsuwan T, Liabsuetrakul T, Ditsuwan V, Thammapalo S. Feasibility of ultra-low-volume indoor space spraying for dengue control in Southern Thailand. Trop Med Int Health. 2013;18(2):230–6.
11. Orellano PW, Pedroni E. Cost-benefit analysis of vector control in areas of potential dengue transmission. Rev Panam Salud Publica. 2008;24(2):113–9.
12. Shepard DS, Suaya JA, Halstead SB, et al. Cost-effectiveness of a pediatric dengue vaccine. Vaccine. 2004;22(9–10):1275–80.
13. Carrasco LR, Lee LK, Lee VJ, et al. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore. PLoS Negl Trop Dis. 2011;5(12):e1426.
14. Lee BY, Connor DL, Kitchen SB, et al. Economic value of dengue vaccine in Thailand. Am J Trop Med Hyg. 2011;84(5):764–72.
15. Durham DP, Ndeffo Mbah ML, Medlock J, et al. Dengue dynamics and vaccine cost-effectiveness in Brazil. Vaccine. 2013;31(37):3957–61.
16. Mahoney RT, Francis DP, Frazatti-Gallina NM, Precioso AR, Raw I, Watler P, Whitehead P, Whitehead SS. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine. 2012;30(32):4892–6.
17. Luz PM, Vanni T, Medlock J, Paltiel AD, Galvani AP. Dengue vector control strategies in an urban setting: an economic modelling assessment. Lancet. 2011;377(9778):1673–80.
18. Suaya JA, Shepard DS, Chang MS, et al. Cost-effectiveness of annual targeted larviciding campaigns in Cambodia against the dengue vector Aedes aegypti. Trop Med Int Health. 2007;12(9):1026–36.
19. Shepard DS, Undurraga EA, Lees RS, Halasa Y, Lum LC, Ng CW. Use of multiple data sources to estimate the economic cost of dengue illness in Malaysia. Am J Trop Med Hyg. 2012;87(5):796–805.
20. Armien B, Suaya JA, Quiroz E, et al. Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama. Am J Trop Med Hyg. 2008;79(3):364–71.
21. Wettstein ZS, Fleming M, Chang AY, et al. Total economic cost and burden of dengue in Nicaragua: 1996–2010. Am J Trop Med Hyg. 2012;87(4):616–22.
22. Halasa YA, Shepard DS, Zeng W. Economic cost of dengue in Puerto Rico. Am J Trop Med Hyg. 2012;86(5):745–52.
23. Beaute J, Vong S. Cost and disease burden of dengue in Cambodia. BMC Public Health. 2010;10:521.
24. Baly A, Toledo ME, Rodriguez K, et al. Costs of dengue prevention and incremental cost of dengue outbreak control in Guantanamo, Cuba. Trop Med Int Health. 2012;17(1):123–32.
25. Guzman MG, Triana C, Bravo J, Kouri G. The estimation of the economic damages caused as a consequence of the epidemic of hemorrhagic dengue in Cuba in 1981. Rev Cubana Med Trop. 1992;44(1):13–7.
26. Clark DV, Mammen MP Jr, Nisalak A, Puthimethee V, Endy TP. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am J Trop Med Hyg. 2005;72(6):786–91.
27. Harving ML, Ronsholt FF. The economic impact of dengue hemorrhagic fever on family level in Southern Vietnam. Dan Med Bull. 2007;54(2):170–2.
28. Huy R, Wichmann O, Beatty M, et al. Cost of dengue and other febrile illnesses to households in rural Cambodia: a prospective community-based case-control study. BMC Public Health. 2009;9:155.
29. Tam PT, Dat NT, le Huu M, et al. High household economic burden caused by hospitalization of patients with severe dengue fever cases in Can Tho province, Vietnam. Am J Trop Med Hyg. 2012;87(3):554–8.
30. Van Damme W, Van Leemput L, Por I, Hardeman W, Meessen B. Out-of-pocket health expenditure and debt in poor households: evidence from Cambodia. Trop Med Int Health. 2004;9(2):273–80.
31. Torres MI. Impact of an outbreak of dengue fever: a case study from rural Puerto Rico. Hum Organ. 1997;56(1):19–27.
32. Baly A, Toledo ME, Boelaert M, et al. Cost effectiveness of Aedes aegypti control programmes: participatory versus vertical. Trans R Soc Trop Med Hyg. 2007;101(6):578–86.
33. Taliberti H, Zucchi P. Direct costs of the dengue fever control and prevention program in 2005 in the city of Sao Paulo. Rev Panam Salud Publica. 2010;27(3):175–80.
34. Valdes LG, Mizhrahi JV, Guzman MG. Economic impact of dengue 2 epidemic in Santiago de Cuba, 1997. Rev Cubana Med Trop. 2002;54(3):220–7.
35. Okanurak K, Sornmani S, Indaratna K. The cost of dengue hemorrhagic fever in Thailand. Southeast Asian J Trop Med Public Health. 1997;28(4):711–7.
36. Ditsuwan T, Liabsuetrakul T, Ditsuwan V, Thammapalo S. Cost of standard indoor ultra-low-volume space spraying as a method to control adult dengue vectors. Trop Med Int Health. 2012;17(6):767–74.
37. Tarragona S, Monteverde M, Marchioni S, Caporale J, Pereiro AC, Palacios JM. Dengue in Argentina: an economic analysis of the impact of the 2009 epidemic. Salud colectiva. 2012;8(2):151–62.
38. Baly A, Flessa S, Cote M, et al. The cost of routine Aedes aegypti control and of insecticide-treated curtain implementation. Am J Trop Med Hyg. 2011;84(5):747–52.
39. Stahl HC, Butenschoen VM, Tran HT, et al. Cost of dengue outbreaks: literature review and country case studies. BMC Public Health. 2013;13:1048.
40. Von Allmen SD, Lopez-Correa RH, Woodall JP, Morens DM, Chiriboga J, Casta-Velez A. Epidemic dengue fever in Puerto Rico, 1977: a cost analysis. Am J Trop Med Hyg. 1979;28(6):1040–4.
41. Anderson KB, Chunsuttiwat S, Nisalak A, et al. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet. 2007;369(9571):1452–9.
42. Pepin KM, Marques-Toledo C, Scherer L, Morais MM, Ellis B, Eiras AE. Cost-effectiveness of novel system of mosquito surveillance and control, Brazil. Emerging infectious diseases. 2013;19(4):542–50.
43. Anez G, Balza R, Valero N, Larreal Y. Economic impact of dengue and dengue hemorrhagic fever in the state of Zulia, Venezuela, 1997–2003. Rev Panam Salud Publica. 2006;19(5):314–20.
44. Garg P, Nagpal J, Khairnar P, Seneviratne SL. Economic burden of dengue infections in India. Trans R Soc Trop Med Hyg. 2008;102(6):570–7.
45. Suaya JA, Shepard DS, Siqueira JB, et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg. 2009;80(5):846–55.
46. Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg. 2011;84(2):200–7.
47. Shepard DS, Undurraga EA, Halasa YA. Economic and disease burden of dengue in Southeast Asia. PLoS Negl Trop Dis. 2013;7(2):e2055.
48. McConnell KJ, Gubler DJ. Guidelines on the cost-effectiveness of larval control programs to reduce dengue transmission in Puerto Rico. Rev Panam Salud Publica. 2003;14(1):9–16.